Genelux Says Frontiers In Oncology Published Case Report Of Platinum-Relapsed Small Cell Lung Cancer Patient Achieving 16.7 Months Progression-Free Survival And 84.6% Target Lesion Reduction After Olvi-Vec And Platinum Rechallenge

Loading news article.

Genelux Says Frontiers In Oncology Published Case Report Of Platinum-Relapsed Small Cell Lung Cancer Patient Achieving 16.7 Months Progression-Free Survival And 84.6% Target Lesion Reduction After Olvi-Vec And Platinum Rechallenge | WAPE

Genelux Says Frontiers In Oncology Published Case Report Of Platinum-Relapsed Small Cell Lung Cancer Patient Achieving 16.7 Months Progression-Free Survival And 84.6% Target Lesion Reduction After Olvi-Vec And Platinum Rechallenge

Article summary

Related companies

Analyzed by WAPE AI.

Comments —